Skip to main content

Biogen International GmbH v. Mylan Pharmaceuticals Inc.

Certiorari Denied

Petition for certiorari denied on October 3, 2022.

Docket No.21-1567
Op. BelowFed. Cir.
SCOTUS Page

Issue

Whether 35 U.S.C. § 112"s requirement that a patent specification "contain a written description of the invention" is met when the specification describes the invention, or whether the specification must also disclose data that demonstrates the claimed invention is "effective" and emphasize the claimed invention by singling it out and describing it more than once.

Proceedings & orders timeline

Jun 14, 2022
Petition for a writ of certiorari filed. (Response due July 15, 2022)Jun 30, 2022
Motion to extend the time to file a response from July 15, 2022 to August 15, 2022, submitted to The Clerk.
Jul 1, 2022
Motion to extend the time to file a response is granted and the time is extended to and including August 15, 2022.
Jul 11, 2022
Brief amicus curiae of Chemistry and the Law Division of the American Chemical Society filed.Jul 14, 2022
Brief amicus curiae of New England Legal Foundation filed.Jul 15, 2022
Brief amici curiae of Pharmaceutical Research and Manufacturers of America, et al.Aug 15, 2022
Brief of respondent Mylan Pharmaceuticals Inc. in opposition filed.Aug 30, 2022
Reply of petitioners Biogen International GmbH and Biogen MA Inc. filed. (Distributed)
Aug 31, 2022
DISTRIBUTED for Conference of 9/28/2022.
Oct 3, 2022
Petition DENIED.

Welcome to SCOTUSblog

Tell us a bit about yourself so we can tailor what you see. You can update these any time in your account.